FUBP3 regulates chronic myeloid leukaemia progression through PRC2 complex regulated PAK1‐ERK signalling

The development of resistance and heterogeneity in differential response towards tyrosine kinase inhibitors (TKI) in chronic myeloid leukaemia (CML) treatment has led to the exploration of factors independent of the Philadelphia chromosome. Among these are the association of deletions of genes on de...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Mugdha, Anandram, Seetharam, Ross, Cecil, Srivastava, Sweta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806296/
https://www.ncbi.nlm.nih.gov/pubmed/36478132
http://dx.doi.org/10.1111/jcmm.17584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806296/
https://www.ncbi.nlm.nih.gov/pubmed/36478132
http://dx.doi.org/10.1111/jcmm.17584

Ejemplares similares